Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
27 studies found for:    neurology AND University AND San Francisco | Open Studies | Exclude Unknown
Show Display Options
Rank Status Study
1 Recruiting Brain Development Research Program
Conditions: Brain Disorders;   Aicardi Syndrome
Intervention:
2 Recruiting Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis
Condition: Pediatric Multiple Sclerosis
Intervention:
3 Recruiting Efficacy of Isradipine in Early Parkinson Disease
Condition: Parkinson Disease
Interventions: Drug: Isradipine;   Drug: Placebo (for Isradipine)
4 Recruiting The Human Epilepsy Project
Condition: Focal Epilepsy
Intervention:
5 Recruiting Neurobiological Predictors of Huntington's Disease (PREDICT-HD)
Condition: Huntington Disease
Intervention:
6 Recruiting Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Condition: Alzheimer's Disease
Interventions: Drug: Solanezumab;   Drug: Placebo
7 Recruiting Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Condition: Huntington's Disease
Intervention:
8 Recruiting The Childhood and Adolescent Migraine Prevention Study
Conditions: Migraine;   Migraine Disorders;   Headache
Interventions: Drug: Amitriptyline;   Drug: Topiramate;   Drug: Placebo
9 Recruiting Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Condition: Multiple Sclerosis
Interventions: Drug: Fingolimod;   Drug: other disease-modifying therapy
10 Recruiting Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: TRx0237 200 mg/day;   Drug: Placebo
11 Recruiting Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III
Condition: Intraventricular Hemorrhage
Interventions: Drug: Cathflo Activase;   Other: Normal saline
12 Recruiting Multiple Dose Study of BIIB037 (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: BIIB037 (recombinant, fully human anti-Aβ IgG1 mAb);   Drug: Placebo
13 Recruiting Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours
Condition: Stroke
Interventions: Drug: GM602;   Drug: Matching Placebo (Bacteriostatic Saline) for GM602
14 Recruiting Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
Conditions: Alzheimers Disease;   Dementia;   Alzheimers Disease, Familial
Interventions: Drug: Gantenerumab;   Drug: Solanezumab;   Drug: Matching Placebo (Gantenerumab);   Drug: Matching Placebo (Solanezumab)
15 Recruiting DFN-02 Open Label Safety Study in Patients With Acute Migraine
Condition: Acute Migraine
Intervention: Drug: DFN-02
16 Recruiting Pediatric Open-Label Extension Study
Conditions: Schizophrenia;   Autism;   Bipolar Depression
Intervention: Drug: Lurasidone 20, 40, 60, 80 mg, flexibly dosed
17 Recruiting Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Condition: Cognition Disorders
Interventions: Drug: Solanezumab;   Drug: Placebo
18 Recruiting A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
Conditions: Glioblastoma;   Small Cell Glioblastoma;   Giant Cell Glioblastoma;   Gliosarcoma;   Glioblastoma With Oligodendroglial Component;   Recurrent Glioblastoma;   Relapsed Glioblastoma
Interventions: Drug: Bevacizumab;   Drug: Rindopepimut (CDX-110) with GM-CSF;   Drug: KLH
19 Recruiting Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Condition: Behavioral Variant Frontotemporal Dementia (bvFTD)
Interventions: Drug: TRx0237;   Drug: Placebo
20 Recruiting Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Condition: HER2 Low to Intermediate Breast Cancer
Interventions: Biological: NeuVax™ vaccine;   Biological: Leukine® (sargramostim, GM-CSF) and water for injection

   Previous Page Studies Shown (1-20) Next Page (21-27) Show next page of results    Last Page
Indicates status has not been verified in more than two years